Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia

por Kosmas, Constantine E, Silverio, Delia, Ovalle, Julio, Montan, Peter D, Guzman, Eliscer
Publicado 2018

Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease

por Kosmas, Constantine E, Sourlas, Andreas, Silverio, Delia, Montan, Peter D, Guzman, Eliscer
Publicado 2019

Primary genetic disorders affecting high density lipoprotein (HDL)

por Kosmas, Constantine E, Silverio, Delia, Sourlas, Andreas, Garcia, Frank, Montan, Peter D, Guzman, Eliscer
Publicado 2018

Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus

por Kosmas, Constantine E, Silverio, Delia, Sourlas, Andreas, Garcia, Frank, Montan, Peter D, Guzman, Eliscer
Publicado 2018

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy

por Kosmas, Constantine E, DeJesus, Eddy, Morcelo, Rosmery, Garcia, Frank, Montan, Peter D, Guzman, Eliscer
Publicado 2017

The Impact of Insulin Resistance and Chronic Kidney Disease on Inflammation and Cardiovascular Disease

por Kosmas, Constantine E, Silverio, Delia, Tsomidou, Christiana, Salcedo, Maria D, Montan, Peter D, Guzman, Eliscer
Publicado 2018

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential

por Kosmas, Constantine E, Muñoz Estrella, Alba, Skavdis, Andreas, Peña Genao, Edilberto, Martinez, Ian, Guzman, Eliscer
Publicado 2020

New and emerging lipid-modifying drugs to lower LDL cholesterol

por Kosmas, Constantine E, Pantou, Dafni, Sourlas, Andreas, Papakonstantinou, Evangelia J, Echavarria Uceta, Rogers, Guzman, Eliscer
Publicado 2021

Insulin resistance and cardiovascular disease

por Kosmas, Constantine E., Bousvarou, Maria D., Kostara, Christina E., Papakonstantinou, Evangelia J., Salamou, Evdokia, Guzman, Eliscer
Publicado 2023

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia

por Kosmas, Constantine E., Muñoz Estrella, Alba, Sourlas, Andreas, Silverio, Delia, Hilario, Elizabeth, Montan, Peter D., Guzman, Eliscer
Publicado 2018

Safety and Tolerability of PCSK9 Inhibitors: Current Insights

por Kosmas, Constantine E, Skavdis, Andreas, Sourlas, Andreas, Papakonstantinou, Evangelia J, Peña Genao, Edilberto, Echavarria Uceta, Rogers, Guzman, Eliscer
Publicado 2020

Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia

por Kosmas, Constantine E, Bousvarou, Maria D, Sourlas, Andreas, Papakonstantinou, Evangelia J, Peña Genao, Edilberto, Echavarria Uceta, Rogers, Guzman, Eliscer
Publicado 2022

The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease

por Kosmas, Constantine E., Rodriguez Polanco, Shanna, Bousvarou, Maria D., Papakonstantinou, Evangelia J., Peña Genao, Edilberto, Guzman, Eliscer, Kostara, Christina E.
Publicado 2023

Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)

por Kosmas, Constantine E., Bousvarou, Maria D., Papakonstantinou, Evangelia J., Tsamoulis, Donatos, Koulopoulos, Andreas, Echavarria Uceta, Rogers, Guzman, Eliscer, Rallidis, Loukianos S.
Publicado 2023

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease

por Kosmas, Constantine E, Martinez, Ian, Sourlas, Andreas, Bouza, Kyriaki V, Campos, Frederick N, Torres, Verenisse, Montan, Peter D, Guzman, Eliscer
Publicado 2018

Therapeutic management of hyperlipoproteinemia (a)

por Kosmas, Constantine E, Sourlas, Andreas, Mallarkey, Gordon, Silverio, Delia, Ynoa, Domingo Y, Montan, Peter D, Guzman, Eliscer, Garcia, Mario J
Publicado 2019